

METHOD

Open Access



CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA

Shuli Kang¹, Qingjiao Li¹, Quan Chen¹, Yonggang Zhou^{2,3}, Stacy Park⁴, Gina Lee⁵, Brandon Grimes⁴, Kostyantyn Krysan⁴, Min Yu⁶, Wei Wang⁷, Frank Alber¹, Fengzhu Sun¹, Steven M. Dubinett^{2,8,9,10*}, Wenyuan Li^{2*} and Xianghong Jasmine Zhou^{2,3*}

Abstract

We propose a probabilistic method, CancerLocator, which exploits the diagnostic potential of cell-free DNA by determining not only the presence but also the location of tumors. CancerLocator simultaneously infers the proportions and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA methylation data. CancerLocator outperforms two established multi-class classification methods on simulations and real data, even with the low proportion of tumor-derived DNA in the cell-free DNA scenarios. CancerLocator also achieves promising results on patient plasma samples with low DNA methylation sequencing coverage.

Keywords: Cell-free DNA, Liquid biopsy, DNA methylation, Next-generation sequencing, Cancer diagnosis

Background

Cancer cells often display aberrant DNA methylation patterns, such as hypermethylation of the promoter regions of tumor suppressor genes and pervasive hypomethylation of intergenic regions [1–5]. Therefore, DNA methylation is an ideal target for cancer diagnosis in clinical practice [6, 7]. Hyper/hypomethylated tumor DNA fragments can be released into the bloodstream via cell apoptosis or necrosis, where they become part of the circulating cell-free DNA (cfDNA) in plasma [8]. The non-invasive nature of cfDNA methylation profiling makes it a promising strategy for general cancer screening. Current research on cfDNA-based, non-invasive cancer detection approaches falls into two classes: the development of biomarkers for a single specific cancer type; and the characterization of circulating tumor DNA (ctDNA) for general cancer detection, without trying to predict specific cancer types.

In recent years, several studies have reported plasma methylation biomarkers for different types of cancers [9–15]. Usually, the differentially methylated marker

genes are identified by comparing methylation profile data from patients with a certain cancer type to healthy controls. However, these specific biomarkers are of limited use for general cancer screening. Ideally, as a non-invasive early screening tool, a liquid biopsy test should be able to detect many types of cancers and provide tumor location information for further specific clinical investigation.

Several approaches have recently been proposed for non-invasive universal cancer detection. These methods do not rely on detecting biomarkers specific to certain tumor types. Instead, they utilize properties of ctDNA that are common to various cancer types, such as copy number aberration (CNA) [16–19], pervasive hypomethylation [19], and DNA integrity [16, 20]. None of these methods can predict the tissue of origin after the detection of ctDNA. The nature of the liquid biopsy introduces a new challenge, in that the cancer type can remain unknown even when there is strong signal of tumor-derived DNA fragments in the blood. Hence, a positive result from a liquid biopsy would call for comprehensive follow-up investigations using clinical, analytical, and radiological tools to identify the tumor location. Considering that non-invasive screening is usually the first step of cancer diagnosis, and could be associated with a fair ratio of false positives, such

* Correspondence: sdubinett@mednet.ucla.edu; WenyuanLi@mednet.ucla.edu; XJZhou@mednet.ucla.edu

²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
Full list of author information is available at the end of the article

follow-up would be likely to increase the burden on the medical care system. A few recent studies have proposed using cfDNA methylation [21, 22] or nucleosome footprinting [23] to partially alleviate this problem. For example, Sun et al. [21] estimated the proportions of cfDNAs contributed by different tissues and showed that an abnormally high proportion of cfDNA from a specific tissue can indicate the possibility of a tumor in that tissue. Their approach, though promising, has not been developed into a systematic method capable of supporting clinical diagnosis applications. Lehmann-Werman et al. [22] tested the same rationale to diagnose pancreatic cancer, but fewer than 50% of the pancreatic cancer patients demonstrated a substantial excess of pancreas-originated cfDNA fragments compared with healthy subjects. Snyder et al. [23] pioneered an approach of using nucleosome footprinting to predict the tissue of origin of the cfDNA, but its power in cancer diagnosis has not been demonstrated because only five plasma samples with high ctDNA burden were selected for testing from 44 late-stage cancer patients, and less than one half had their cancer types correctly predicted.

In summary, no existing cfDNA-based method can simultaneously detect cancer and predict its tissue of origin. We are therefore proposing a novel method, CancerLocator, that simultaneously infers the proportion

and tissue of origin of ctDNA in a blood sample using genome-wide DNA methylation data. As shown in Fig. 1, from the vast amount of The Cancer Genome Atlas (TCGA) DNA methylation data, we first learn the informative features of different cancer types. We then model the plasma cfDNAs in cancer patients as a mixture of normal cfDNAs and ctDNAs. Finally, given the genome-wide methylation profile derived from the cfDNA sample of an unknown patient, CancerLocator uses the informative features to estimate the fraction of ctDNAs in the plasma and the likelihood that the detected ctDNAs come from each tumor type. Based on those likelihoods, CancerLocator makes the final decision on whether the patient has tumors and, if yes, the locations of the primary tumor.

We first evaluated our method on simulation data with known ctDNA fractions. The results show that CancerLocator can achieve a Pearson’s correlation coefficient (PCC) of 0.975 between the predicted and true proportions of ctDNA, and an error rate of 0.078 for the classification of non-cancer and tumor types. Moreover, our method far outperforms two well-established multi-class classification methods in both simulations and using real data, especially when the proportion of tumor-derived DNAs in the cfDNAs is lower than 50% (which is usually the case in reality). We note that




Fig. 1 Flowchart of CancerLocator. Step 1: A set of solid tumor samples and healthy plasma samples collected from public databases and the literature are used to select the informative features (CpG clusters) that can differentiate tumor types or healthy plasma samples. Then the beta distributions of the methylation levels of these selected features for each tumor type or healthy plasma samples are learnt. Step 2: Given a plasma sample, the methylation profile of its cfDNAs is measured by whole-genome bisulfite sequencing, which is then used as input for cancer location prediction by CancerLocator

CancerLocator achieved promising results on patient plasma samples, including around two-thirds of cancer samples collected from early-stage cancer patients.

Results and discussion

CancerLocator: a probabilistic method for predicting ctDNA burden and source tissue

A flowchart of CancerLocator is illustrated in Fig. 1. The first step is to identify the informative features of normal plasma and multiple tumor types from the massive TCGA database. We chose to focus on seven cancer types from the five organs (breast, colon, kidney, liver, and lung) that are generally regarded as having a high level of blood circulation. Given the plasma cfDNA methylation profile of a patient, the next step is to use those informative features to simultaneously detect cancer and locate its tissue of origin.

In the first step, we select CpG clusters (our procedure for grouping CpG sites into CpG clusters is described in the “Methods” section) as features if their methylation range (MR) is sufficiently large. MR is defined as the range of average methylation levels observed in healthy plasma and different solid tumor tissues. We selected $K = 14,429$ CpG clusters (features), on average¹, whose MRs are no less than the cutoff 0.25. For each CpG cluster, we take into account its variation across individuals by modeling the distribution of methylation levels for the same tumor type (or normal plasma) as a beta distribution, $\text{Beta}(\alpha_v, \beta_v)$. The index $t = 0$ represents normal plasma, while $t = 1, \dots, T$ represents a tumor type.

In the second step, we use the selected features and their beta distributions to deconvolute a patient’s plasma cfDNA into the normal plasma cfDNA distribution and, possibly, a solid tumor DNA distribution. We have designed a probabilistic method that can simultaneously infer the burden and the tissue of origin of the ctDNA. Intuitively, if the likelihood of presence for any tumor type is not substantially higher than the likelihood that the observed distribution is the normal background, the patient is predicted to not have cancer. Otherwise, the patient is predicted to have the tumor type that is associated with the highest likelihood.

Inferring the ctDNA burden θ and tumor type t can be formulated as a maximum-likelihood estimation (MLE) problem, where the likelihood function is expressed as the product of the likelihoods of each CpG cluster, assuming that all of the K selected CpG clusters are independent of each other. This is expressed as:

$$L(\theta, t|X) = \prod_{k=1}^K L(\theta, t|x_k)$$

where x_k denotes the methylation level of CpG site k in a cancer patient’s cfDNA. In principle, x_k is a linear combination of the DNA methylation levels in normal


plasma and solid tumor type t with fraction θ . The normal and tumor components of the methylation are denoted by v_k and u_k , respectively (Fig. 2). That is, $x = (1 - \theta)v + \theta u$ (for simplicity, we remove the subscript k from these notations). As mentioned earlier, since v and u follow the Beta distributions $\text{Beta}(\alpha_0, \beta_0)$ and $\text{Beta}(\alpha_t, \beta_t)$, respectively, x follows the distribution $\psi(\theta, t)$, which is calculated as the convolution of two Beta distributions $\text{Beta}(\alpha_0, \beta_0)$ and $\text{Beta}(\alpha_t, \beta_t)$.

Because cfDNA has low abundance in plasma, its methylation is usually measured by sequencing-based methods. Therefore, the methylation level x_k of CpG cluster k can be derived from two numbers, n_k and m_k , denoting the total number of cytosines and the number of methylated cytosines mapped to CpG cluster k . We can model m_k and n_k together as a binomial distribution $m_k \sim \text{Binomial}(n_k, x_k)$, and rewrite the likelihood function as:

$$L(\theta, t|M, N) = \prod_{k=1}^K L(\theta, t|m_k, n_k)$$

Detailed formulas and our optimization method are given in the “Methods” section.

For a comprehensive performance evaluation, we compare our method with two popular multi-class classification



methods, i.e., random forest (RF) and support vector machine (SVM), on two types of data: simulation data with known ctDNA burden and real data with known clinical information but unknown ctDNA burden. The evaluations on simulation data and real data are complementary in assessing the predictive power of the methods.

Prediction performance on the simulation data

The methylation data of a simulated plasma cfDNA sample is generated by computationally mixing the entire methylation profiles of a normal plasma cfDNA sample and a solid tumor sample (breast, colon, kidney, liver, or lung tumors), at a variety of ctDNA burdens (θ values). This strategy can make the simulated methylation data keep the potential correlations of methylation values between CpG clusters in real data. In addition, to make the simulated data more realistic, we add tumor CNA events at pre-defined probabilities (10, 30, and 50% across all CpG clusters). The procedure for these simulations is described in the “Methods” section. The results described below are on the simulation dataset with 30% CNA events—simulation data with other CNA event rates yield similar results (Additional file 1).

We first assessed CancerLocator for ctDNA burden predictions. Overall, the predicted and true proportions of ctDNA are highly consistent, with a Pearson’s correlation coefficient of 0.975 and a root mean squared error of 0.074, respectively. As shown in Fig. 3a, the majority (87.9%) of the estimated ctDNA burdens for the normal samples are not more than 0.02, and none of them is greater than 0.05. Please note that whether a sample is from a cancer patient or not is determined by the optimal likelihood calculated in the prediction model, not the predicted ctDNA burden. The prediction results for the simulated cancer patient plasma samples are shown in Fig. 3b. We found that the variance of the predicted ctDNA burdens (θ) increases with the true θ , implying that the burden estimation becomes less precise when patients are in mid- or late cancer stages. This result could be partially explained by the fact that tumor heterogeneity may be higher in late stage tumor samples, which introduces the complexity of ctDNA burden prediction. However, this increased variance does not hurt the performance of the cancer detection because the predicted θ is still much higher than the normal background. Indeed, as demonstrated in Fig. 3b and below in the cancer type prediction results, the tissue origin of ctDNA becomes more distinguishable with high ctDNA burden, despite the increased variance in ctDNA prediction.

We then compared the performance of CancerLocator to that of two popular multi-class classification methods (RF and SVM; refer to Additional file 1 for details) using the same set of simulated samples. For a systematic comparison, we divided the simulation data into ten





Fig. 3 The predicted ctDNA burden for simulated normal and cancer plasma samples. **a** Predicted ctDNA burdens for normal samples whose true ctDNA burden should be zero. **b** Predicted and true ctDNA burdens for cancer samples. Each dot represents a prediction with the true (*x-axis*) and predicted (*y-axis*) ctDNA burdens. The correct and incorrect predictions are represented by cyan and red, respectively, in both **a** and **b**

subsets for different cancer stages, each of which includes 200 normal plasma samples and 200 cancer plasma samples of each tumor type. The different cancer stages (from early, mid-, to late stages) are represented by a set of ctDNA burden ranges ($\theta, \theta + 10\%$], where $\theta = 0, 10, 20, 30, 40, 50, 60, 70, 80,$ and 90% . For a six-class classification problem (normal, breast, colon, kidney, liver, and lung), we adopt the *error rate* measure for assessing the classification performance (see “Methods”). The results are shown in Fig. 4. For early-stage cancer patients with ctDNA burdens in the range $\theta \in (0, 10\%]$, CancerLocator (error rate 0.240) largely outperforms RF and SVM (error rates 0.807 and 0.816, respectively), which are only slightly better than random guesses (0.833). For the second lowest ctDNA burdens $\theta \in (10\%, 20\%]$, CancerLocator reaches a very high prediction performance (error rate 0.067), while RF and SVM still have very poor performance (0.735 and 0.712, respectively). The two competing methods do not perform well until the ctDNA burdens are greater than 50%,



which is mainly seen in plasma samples of late-stage cancer patients. The superior performance of CancerLocator on low to moderate ctDNA fractions indicates that without considering the mixture nature of cfDNAs in plasma, existing popular classification methods always fail to distinguish normal plasma samples and cancer patients' plasma samples. This result highlights the advantage of our method for cancer diagnosis.

Prediction performance on real plasma data

We randomly chose 75% of solid tumor samples and healthy plasma cfDNA samples as a training set to learn features. The remaining healthy plasma samples and all the cfDNA samples collected from cancer patients form

the testing set, to which we applied CancerLocator, RF and SVM based on the selected features. After performing this procedure (including random data partition and predictions) ten times, the predictions of each of the three methods in ten runs were summarized into a confusion matrix, as shown in Table 1. Refer to the "Methods" section for detailed description of this procedure. For a new patient's plasma sample, we assume that we have no prior information about the cancer type. Therefore, we also consider colon and kidney tumor as possible results, even though our real plasma data include no plasma samples from colon or kidney cancer patients.

The results in Table 1 show that our method vastly outperforms the two competing methods (RF and SVM).

Table 1 Confusion matrix of prediction results on the real plasma samples

Method	True class	Predicted class					
		Breast	Colon	Kidney	Liver	Lung	Non-cancer
CancerLocator	Breast	20	0	0	0	0	30
	Liver	0	0	20	233	33	4
	Lung	14	0	0	10	68	28
	Non-cancer	0	0	10	17	1	142
Random forest	Breast	0	0	1	0	1	48
	Liver	3	3	10	53	7	214
	Lung	4	0	1	0	1	114
	Non-cancer	0	0	0	1	0	169
SVM	Breast	0	0	0	0	15	35
	Liver	0	0	13	66	34	177
	Lung	0	0	1	0	26	93
	Non-cancer	0	0	1	0	12	157

Numbers in bold are correct predictions

In fact, the competing methods cannot distinguish most cancer samples from non-cancer samples. Specifically, all the breast samples and the majority of liver and lung cancer samples are wrongly predicted as non-cancer by both RF and SVM. The overall error rates of RF and SVM are 0.646 and 0.604, respectively. In contrast, CancerLocator obtains a low error rate of 0.265 for the six-class prediction problem. These results are consistent with the simulation experiments for ctDNA burdens lower than 50%.

To understand the relationship between estimated ctDNA burdens and tumor types in real data, we plotted their relationships in Fig. 5 by summarizing predictions for each plasma sample in all ten runs: the average estimated ctDNA burden (y-axis value) and the most frequently predicted tumor type (dot color) among ten runs for each sample. It can be observed that the higher the estimated ctDNA burden, the more accurate the prediction of tumor type. This is highly consistent with the results from the simulation data. For the breast cancer samples, three out of five samples have ctDNA burdens $\leq 2.2\%$, and they are all predicted as non-cancer. The inferred tumor burden of the two correctly predicted samples are 5.0 and 18.0%, respectively, and the latter is a metastatic sample. For the 29 liver cancer samples, at least 25 of them are from early-stage (Barcelona Clinic Liver Cancer stage A) patients. Most of them (80%) were classified as liver cancer and all of them were detected as cancer samples. Compared to the breast cancer samples, most of the liver samples, even at an early stage, can have moderate to high tumor burden (average predicted tumor burden of 14.9% and the highest reaching 59.0%), given that liver has generally excellent blood circulation, but we also correctly classified the one with only 2.0% predicted tumor burden as liver cancer.

Among the 12 lung cancer samples (two samples did not have cancer stage information), at least five were collected from early-stage patients. These early-stage samples have predicted tumor burdens ranging from 2.0 to 4.0%. Among these five early-stage lung cancer samples, four were correctly predicted as lung cancer, whereas the remaining one was predicted as non-cancer.

We also note that CancerLocator correctly predicted seven out of eight chronic hepatitis B virus (HBV) samples to be non-cancer samples. In addition, our method successfully predicted the only one sample with benign lung tumor as non-cancer in all ten runs, with the predicted ctDNA burden always being 0.0%. These results demonstrate that CancerLocator can go beyond distinguishing healthy samples from cancer samples and handle more sophisticated scenarios, such as differentiating HBV carriers or benign tumor patients from cancer patients.

Conclusions

Blood-based cancer diagnosis, unlike traditional diagnosis based on tissue biopsy, has the potential to diagnose tumors from many organs. The proposed CancerLocator aims to exploit this potential of cfDNA by not only diagnosing the presence of tumors, but also predicting the tissue of origin. Although three very recent studies have investigated the inference of tissue of origin [21–23], these works lack either a well-developed prediction method [21] or systematic performance evaluations [22, 23]. Unlike these previous studies, we lay out a systematic prediction method for cfDNA-based cancer type inference, comprehensively evaluate its performance on both simulated data and real data, and compare its performance to that of two established multi-class classification methods. We show that having a




Fig. 5 The relationship between ctDNA burden and tumor tissue prediction for each plasma sample of the real data. Each point represents a real plasma sample. This plot illustrates the average estimated tumor burden (y-axis) and the most frequently predicted tumor type (dot color) among ten runs for each plasma sample

mixture of plasma cfDNAs can completely defeat standard machine learning methods for cancer type predictions when the proportion of tumor-derived DNA is lower than 50%. In contrast, CancerLocator successfully overcomes this obstacle. The poor performance of the standard methods is largely caused by their treatment of the samples in each tumor class as independent and identically distributed, following some class-specific distribution, while in our model the samples from the same class can still be very different due to different ctDNA percentages in the blood. In addition, our results show that our method is robust to CNA events, possibly because the genome-wide features outweigh the local aberrations.

In this work, we used DNA methylation microarrays of solid tumor tissues to train the model due to the scarcity of whole-genome bisulfite sequencing data (WGBS) in the public domain. Since DNA methylation arrays focus only on promoter regions, they may miss important signature regions of cancer. Therefore, we expect that the growing amount of WGBS data will significantly empower the proposed approach by revealing better and higher resolution signatures. Owing to the limited number of plasma samples, the results of this study are evaluated only on three cancer types (breast, liver and lung). However, our new approach has the potential to perform well on all cancer types with well-circulated originating organs. Also, due to the limited plasma samples, the cutoff of the prediction score λ (defined in the “Methods” section and computed based on the likelihood) used to differentiate cancer or non-cancer samples is specifically determined for this set of plasma samples for the best performance. When data on more plasma samples become available, this cutoff could be determined by the training data to be robust to most testing scenarios. Finally, we note that we identified markers by comparing methylation profiles of normal plasma cfDNAs and tumor DNAs. This procedure may introduce markers that are tissue-specific but not tumor-specific. This effect can be largely reduced by first using paired samples (tumor sample and the matched adjacent non-tumor sample) to identify tumor-specific markers, then further narrowing down to those markers that show differentiating signals from normal plasma cfDNAs. We foresee the increased power by such identified biomarkers when sufficient paired samples become available.

Methods

In this section, we describe: 1) how the data are processed (including methylation microarray and sequencing data); 2) the implementation of CancerLocator; 3) how the simulation data are generated while taking into account copy number aberrations; 4) how the training and testing data are split; and 5) what measures we use to evaluate performance.

Methylation data collection and processing

Data collection

We collect a large set of public methylation data of solid tumors and plasma cfDNA samples taken from both healthy people and cancer patients. The majority of tumor methylation profiles in TCGA were assayed using the Infinium HumanMethylation450 microarray. We collect those data for solid tumors with >100 samples from five different organs: 681 samples of breast (BRCA), 290 samples of colon (COAD), 522 samples of kidney (including 300 KIRC and 156 KIRP samples), 169 samples of liver (LIHC), and 809 samples of lung (including 450 LUAD and 359 LUSC samples) cancer.²

The public methylation data of plasma cfDNA samples are from Chan et al. [19] and Sun et al. [21]. The two datasets include the WGBS data of plasma samples taken from 32 normal people, eight patients infected with HBV, 29 liver cancer patients, four lung cancer patients, five breast cancer patients, and a number of patients with tumors in organs without a large blood flow. We also generated WGBS data from plasma samples collected from eight cancer patients (five early-stage lung cancer patients, one late-stage lung cancer patient, two lung cancer patients with unknown stage information) and one patient with a benign lung tumor. We used only the normal, HBV, and breast/liver/lung cancer patients in our study, for a total of 87 plasma samples. Note that these public WGBS data have very low sequencing coverage (~4× on average), while the coverage of our newly generated data for all nine samples is around 10×.

Human subjects

The blood samples of eight lung cancer patients and one benign lung tumor patient were collected. The demographic and clinical features of the patients profiled are presented in Additional file 1: Table S2.

Cell-free DNA isolation and whole-genome bisulfite sequencing

Blood samples were centrifuged at 1600 × g for 10 minutes and then the plasma was transferred into new microtubes and centrifuged at 16,000 × g for another 10 minutes. The plasma was collected and stored at -80 °C. cfDNA was extracted from 5 ml plasma using the Qiagen QIAamp Circulating Nucleic Acids Kit and quantified using a Qubit 3.0 Fluorometer (Thermo Fisher Scientific). Bisulfite conversion of cfDNA was performed using a EZ-DNA-Methylation-GOLD kit (Zymo Research). After that, an Accel-NGS Methy-Seq DNA library kit (Swift Bioscience) was used to prepare the sequencing libraries. The DNA libraries were then sequenced with 150-bp paired-end reads.

Building features (CpG clusters)

The Infinium HumanMethylation450 microarray data from TCGA measure all solid tumor samples at ~450,000 CpGs. Since our testing sample [19] comprises WGBS data with very low sequencing coverage, we grouped the CpG sites into CpG clusters in order to use more mappable reads. For a CpG site covered by a probe on the microarray, we define the region 100 bp up- and downstream as its flanking region and assume that all CpG sites located within this region have the same average methylation level as the CpG sites covered by probes. Two adjacent CpG sites are grouped into a CpG cluster if their flanking regions overlap. Finally, only those CpG clusters containing at least three CpGs covered by microarray probes are used in this study. We choose the size of the flanking region and the number of CpGs in a cluster according to three criteria: (i) at least three CpG sites (in the microarray data) are included to obtain a robust measurement of methylation values in the solid tumor samples; (ii) the cluster is reasonably sized, so that there are sufficient CpG sites to calculate the methylation values, even when low coverage sequencing data are used; (iii) keep as many clusters that span within a type of genomic region (either CpG islands or shores) as possible. This procedure yielded 42,374 CpG clusters, which together include about one-half of all the CpG sites on the Infinium HumanMethylation450 microarray. Most of these clusters are each associated with only one gene. These CpG clusters are used for subsequent feature selection.

Methylation microarray data processing

The microarray data (level 3 in TCGA database) provide the methylation levels of individual CpG sites. We define the methylation level of a CpG cluster as the average methylation level of all CpG sites in the cluster. A cluster’s methylation level is marked as “not available” (NA) if more than half of its CpG sites do not have methylation measurements.

WGBS data processing

Bismark [24] is employed to align the reads to the reference genome HG19 and call the methylated cytosines. After the removal of PCR duplications, the numbers of methylated and unmethylated cytosines are counted for each CpG site. The methylation level of a CpG cluster is calculated as the ratio between the number of methylated cytosines and the total number of cytosines within the cluster. However, if the total number of cytosines in the reads aligned to the CpG cluster is less than 30, the methylation level of this cluster is treated as NA.

Feature filtering

For each CpG cluster, we used the methylation range (MR) to indicate a feature’s differential power between

classes. We first obtained the average methylation level of all samples from each class (i.e., healthy plasma or each tumor type), then defined MR as the range of this set of mean values (i.e., the difference between the largest and smallest mean values). The higher the MR of a cluster is, the more differential power it has. Finally, we selected those CpG clusters whose MRs were no lower than a threshold.

Statistical inference of the ctDNA burden and tissue of origin

A mixture model of methylation levels of plasma cfDNAs

The cfDNA in the plasma of cancer patients can be regarded as a mixture of normal background DNA and tumor-released DNA. Formally, for each CpG cluster $k \in \{1, 2, \dots, K\}$, the methylation level x_k of the plasma cfDNA from a given patient can be approximated as a mixture of v_k and u_k , which are the methylation levels of the normal plasma sample and the solid tumor tissue, respectively. Let $\theta \in (0, 1)$ denote the proportion of tumor-derived DNAs in plasma cfDNA. Then x_k can be expressed as the weighted sum of v_k and u_k , i.e., $x_k = (1 - \theta)v_k + \theta u_k$.

We assume that an individual carries at most one type of tumor among the T possible tumor types. Let $t \in \{0, 1, 2, \dots, T\}$ be the variable representing either normal plasma ($t = 0$) or a tumor type ($1 \leq t \leq T$). For each CpG cluster k , we model its methylation level in a sample of type t as a Beta distribution: $v_k \sim \text{Beta}(\alpha_{k0}, \beta_{k0})$ for normal plasma samples ($t = 0$) and $u_k \sim \text{Beta}(\alpha_{kt}, \beta_{kt})$ for solid tumor samples of type $t \in \{1, \dots, T\}$, where α_{k0} and β_{k0} (α_{kt} and β_{kt}) are the parameters of the beta model of methylation levels of CpG cluster k in normal plasma (solid tumor) samples. As illustrated in step 1 of Fig. 1, the parameters of these Beta distributions are estimated by the method of moments, using the large amount of public tumor data and normal plasma data.

By integrating the two Beta distributions (v_k and u_k), as shown in Fig. 2, x_k can be modeled by a derived distribution with the given ctDNA burden θ and source tumor type t . This model is denoted as the probability density function $\psi(x_k|\theta, t)$, which is calculated by the convolution of $\text{Beta}(\alpha_{k0}, \beta_{k0})$ and $\text{Beta}(\alpha_{kt}, \beta_{kt})$. It is formally expressed as:

$$\psi(x_k|\theta, t) = \int_0^1 f_{\text{Beta}}\left(\frac{x_k - \theta u_k}{1 - \theta} | \alpha_{k0}, \beta_{k0}\right) f_{\text{Beta}}(u_k | \alpha_{kt}, \beta_{kt}) du_k \tag{1}$$

where f_{Beta} is the probability mass function of the Beta distribution.

Modeling the methylated cytosine count of plasma cfDNA sequencing data

Due to its low abundance in plasma, the methylation profile of cfDNA is usually measured by sequencing-based methods, and the methylation levels (x_k) of a CpG cluster k can be characterized by the numbers of methylated and unmethylated cytosines in the reads. Let $M = (m_1, m_2, \dots, m_K)$ and $N = (n_1, n_2, \dots, n_K)$ be the number of methylated cytosines and the total number of cytosines mapped to all CpG sites, respectively, where the index runs over all K CpG clusters. For each CpG cluster k , m_k can be modeled by a binomial distribution: $m_k \sim \text{Binomial}(n_k, x_k)$. By integrating the mixture model of x_k in Eq. 1, we have the likelihood function for each CpG cluster k which has the inputs from the model parameters ($\theta, t, \alpha_{k0}, \alpha_{kt}, \beta_{k0}, \beta_{kt}$) and the sequence measurements of plasma samples (m_k, n_k):

$$f(m_k|\theta, t, n_k) = \int_0^1 f_{\text{Binomial}}(m_k|n_k, x_k) \psi(x_k|\theta, t) dx_k \quad (2)$$

where f_{Binomial} is the probability density function of the binomial distribution.

Maximum-likelihood estimation of blood tumor burden and type

Given the methylation sequencing profile of a patient's plasma cfDNA sample, the vectors M and N , we aim to find the maximum-likelihood estimate of two model parameters: a sample's cfDNA tumor burden θ and its source tumor type t . For integrating the mixture models of multiple markers into the formulation, we adopted a commonly used assumption: all features or markers are independent of each other. This assumption has been widely used in a number of cell-type deconvolution studies [25, 26]. Under this assumption, the log-likelihood can be written as:

$$\log L(\theta, t|M, N) = \sum_{k=1}^K \log f(m_k|\theta, t, n_k) \quad (3)$$

Since the integrals in Eqs. 1 and 2 cannot be easily solved analytically, we use Simpson's rule to calculate the log-likelihood. That is, a set of J predefined θ values, $\Theta = \left\{0, \frac{1}{J}, \frac{2}{J}, \dots, \frac{J-1}{J}\right\}$, is used to conduct a grid search for the best estimation (i.e., a global optimization solution). The higher the resolution (J), the more precise the estimation. After obtaining the solution (i.e., $\hat{\theta}$ and \hat{t}) that maximizes Eq. 3, we use the estimated parameters to calculate a simple yet effective prediction score that answers two questions: "Does the patient have cancer?";

and "If the patient has cancer, which tumor type is it?" This prediction score is defined below:

$$\lambda = \frac{1}{K} [\log L(\hat{\theta}, \hat{t}|M, N) - \log L(\theta = 0|M, N)] \quad (4)$$

where the denominator K is used to normalize the log-likelihood, so that λ is comparable when using a different number of features. The variable t is not included in $L(\theta = 0|M, N)$ because $\theta = 0$ indicates a normal plasma sample. The larger the prediction score λ , the higher the chance that the patient has a cancer tumor of type \hat{t} . Specifically, if λ is greater than a threshold, the patient is predicted as having cancer with the ctDNA burden $\hat{\theta}$ and the tumor type \hat{t} ; otherwise, he/she is classified as not having cancer.

Simulation data generation

We simulate the methylation sequencing data of a patient's plasma cfDNAs using the previously described probabilistic models: (i) a mixture model that treats the cfDNA as a mixture of normal plasma cfDNA and DNAs released from primary tumor sites; and (ii) a binomial model for the methylated cytosine count of plasma cfDNA sequencing data. In addition, to make the simulation data more realistic, we incorporate CNAs and read depth bias. The procedure for simulating plasma cfDNA methylation sequencing data is detailed in the following sections.

Inputs

Inputs include: (i) the genomic regions of all K CpG clusters; (ii) the total number of cytosines (Z) on the sequencing reads that are aligned to any CpG cluster; (iii) the range of θ : (θ_L, θ_U); (iv) the collections of normal plasma samples (denoted as $\text{POOL}_{\text{normal}}$) and solid tumor samples (denoted as $\text{POOL}_{\text{tumor}}$); and (v) b_k , the background probability for a CpG dinucleotide to be aligned to CpG cluster k , satisfying $\sum_{k=1}^K b_k = 1$. The last input reflects the read-depth bias introduced during the sequencing process and read alignment and the density of CpG sites in the clusters. Refer to Additional file 1 for details of how to obtain b_k .

Output

Output comprises a simulated methylation sequencing profile of a plasma sample, represented by the integer vectors $M = (m_1, m_2, \dots, m_K)$ and $N = (n_1, n_2, \dots, n_K)$. The elements m_k and n_k are the number of methylated cytosines and the total number of cytosines in the reads mapped to CpG cluster k , respectively.

Procedure

1. Generate a random ctDNA fraction θ from the distribution $\theta \sim \text{Uniform}(\theta_L, \theta_U)$.

2. Generate a random integer copy number c_k for each CpG cluster k , from the categorical distribution $c_k \sim \text{Cat}(6, p_0, p_1, p_2, p_3, p_4, p_5)$. Here, p_c denotes the probability of observing copy number $c \in \{0, 1, 2, 3, 4, 5\}$ in the sequencing data. The probabilities p_c satisfy three criteria: (i) their sum is equal to one, $\sum_{c=0}^5 p_c = 1$; (ii) the average copy number is equal to two, $\sum_{c=0}^5 c * p_c = 2$; and (iii) extreme CNAs are less likely to occur. In this work, we predefine $p_0 = 0.005, p_1 = 0.16, p_2 = 0.7, p_3 = 0.105, p_4 = 0.025, p_5 = 0.005$. Note that the sum of all these probabilities except p_2 (30% in this case) is the probability of any given CpG cluster having a CNA event. We have tried other probability configurations for the simulation with more (50%) or fewer (10%) CNA events and obtained similar results (Additional file 1). No CNA event is considered (i.e., c_k is fixed to two) when simulating a normal plasma sample.
3. Randomly select a normal plasma sample from $\text{POOL}_{\text{normal}}$ whose methylation profile is denoted by (v_1, v_2, \dots, v_K) , and randomly select a solid tumor from $\text{POOL}_{\text{tumor}}$ whose methylation level profile is denoted by (u_1, u_2, \dots, u_K) . Note that we also randomly select two normal plasma samples from $\text{POOL}_{\text{normal}}$ in order to simulate a new normal plasma sample.
4. Calculate the methylation level x_k of plasma cfDNA at CpG cluster k . This is the adjusted linear combination of v_k and u_k after incorporating the copy number c_k generated in step 2. That is, $x_k = (1 - \theta'_k)v_k + \theta'_k u_k$, where θ'_k is the adjusted value of θ given by $\theta'_k = \frac{\theta c_k}{\theta c_k + 2(1-\theta)}$. θ describes the actual ctDNA fraction after considering the copy number c_k of the ctDNA.
5. Generate a random number n_k , representing the total number of cytosines in CpG cluster k , from the Poisson distribution $n_k \sim \text{Poisson}(ZB_k)$. B_k is the adjusted CpG dinucleotide bias b_k , given by

$$B_k = \frac{b_k(1-\theta+\theta c_k/2)}{\sum_{k=1}^K b_k(1-\theta+\theta c_k/2)}$$

after scaling with the copy number c_k generated in step 2.

6. Generate a random number m_k from the binomial distribution $m_k \sim \text{Binomial}(n_k, x_k)$.

Due to the limited number of normal plasma samples, we also simulated new normal plasma samples by mixing two normal plasma samples at different mixture ratios. The procedure is the same as above except that step 2 is ignored by fixing all copy numbers as two because there are no CNA events in the normal plasma samples.

Performance evaluation

Data partitions for learning signature features, simulation, and real data experiments

All TCGA solid tumor tissues and plasma samples are divided into non-overlapping sets for three tasks: (i) learning discriminating features; (ii) simulation experiments; and (iii) testing on the real data. Specifically, as shown in Fig. 6, we split TCGA solid tumors of each tissue type into two partitions: 75% for learning signature features and 25% for generating simulation data. We also split all normal plasma samples into two partitions: 75% for learning signature features and 25% for generating simulation data or for real data experiments. All the plasma samples of the cancer patients are used to form the testing set in the real data experiments. Note that not these plasma samples, but only solid tumor samples collected from public methylation databases, and a subset of normal plasma samples that were not used for testing, were used for learning features. All data are randomly partitioned following the above proportions, and applying a method on one such partition is regarded as “one run”. For making the robust results, we repeat the experiments for ten runs and aggregate all predictions obtained in the ten runs into a single confusion matrix as the final result. Because we had a limited number of




Fig. 6 Illustration of the data partition for learning discriminating features, in both simulation and real data experiments. Note that simulation and real data experiments share the same subset (25%) of normal plasma samples

real cancer plasma samples (only 5, 12, and 29 cfDNA samples from breast, lung, and liver cancer patients, respectively) for testing, it would not allow the typical cross-validation for the method's hyperparameter estimation. For fully utilizing the test samples for effective performance evaluation, we report only the best prediction results for each of three methods (CancerLocator, RF and SVM) after examining all possible values of each method's hyperparameters. The only hyperparameter of CancerLocator is the threshold of the prediction score λ , which is set as 0.023 to generate the predictions on the real plasma samples. For consistency with the real data experiments, we apply the same strategies to simulation data experiments and calculate the error rate averaged over ten runs.

Prediction performance measures

The error rate and accuracy are the most popular and established multi-class classification performance measures [27–29]. They are equivalent to each other. This study uses the error rate, which is defined as the percentage of incorrect predictions out of all predictions.

Endnotes

¹We randomly select a subset of the normal plasma and TCGA tumor samples for training and use the rest to simulate samples for testing. This procedure is repeated ten times. Different training sets may lead to different numbers of selected CpG clusters. We therefore report the average number of features here. Our data partition strategy is illustrated in Fig. 6 and described in the “Methods” section.

²BRCA, Breast invasive carcinoma; COAD, Colon adenocarcinoma; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma.

Additional file

Additional file 1: Supplementary information. A PDF file including Figures S1 and S2, Tables S1 and S2, as well as the details of background bias estimation of CpG read counts, the RF and SVM methods, and CancerLocator's prediction results on simulation data with different levels of CNA events. (PDF 558 kb)

Acknowledgements

This work was supported by the NHLBI MAPGEN U01HL108634 grant to X.J.Z., the NIH/NCI 1U01CA214182-01 and the NIH/NCI 1U01CA196408-01 to S.M.D. Funding for open access charge: National Institutes of Health (NIH) [NHLBI MAPGEN U01HL108634 to X.J.Z.]. The authors greatly acknowledge Dr. Yuk Ming Dennis Lo and his circulating nucleic acids research group in the Chinese University of Hong Kong for his cfDNA data [19, 21]. We also thank Wing Hung Wong for his constructive input for the manuscript.

Availability of data and materials

CancerLocator is implemented in Java and is freely available on GitHub (<https://github.com/jasminezhoulab/CancerLocator>) under the MIT license. The source code is also available at Zenodo (DOI: 10.5281/zenodo.375649). The sequence data of the nine samples collected in this work have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the European Bioinformatics Institute (EBI) and the Centre for Genome Regulation (CRG), under accession number EGAS00001002211.

Authors' contributions

SK, WL, and XJZ conceived the study. SK, WL, QC, and XJZ designed the methodological framework. SK implemented the methods and performed analysis. QL processed the WGBS data of real samples. SP, GL, BG, KK, and SMD provided and processed lung cancer blood samples. YZ performed cfDNA extraction and library preparation. MY provided experimental infrastructures. WW participated in the initial attempt of blood sample collection. SK, WL, and XJZ wrote the manuscript with input from FS, FA, QC, and QL. All authors read and approved the final manuscript.

Competing interests

University of California at Los Angeles and University of Southern California have a patent pending for CancerLocator. The patent, however, does not restrict the research use of CancerLocator.

Ethics approval and consent to participate

All blood samples were collected with informed consent for research use and were approved by University of California at Los Angeles Lung Cancer Translational Research Bank Institutional Review Board (#10-001096) in accordance with the Declaration of Helsinki. All patients were de-identified with samples coded.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Molecular and Computational Biology, University of Southern California, Los Angeles, CA 90089, USA. ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA. ³Institute for Quantitative and Computational Biosciences, University of California at Los Angeles, Los Angeles, CA 90095, USA. ⁴Division of Pulmonary, Critical Care Medicine, Clinical Immunology and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. ⁵VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. ⁶Department of Stem Cell Biology and Regenerative Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. ⁷Clinical Laboratory, Zhejiang Province Tongde Hospital, Hangzhou, Zhejiang Province, People's Republic of China. ⁸Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. ⁹Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. ¹⁰Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA.

Received: 13 January 2017 Accepted: 8 March 2017

Published online: 24 March 2017

References

- Esteller M. Molecular origins of cancer epigenetics in cancer. *N Engl J Med*. 2008;358:1148–59.
- Ross JP, Rand KN, Molloy PL. Hypomethylation of repeated DNA sequences in cancer. *Epigenomics*. 2010;2:245–69.
- Yang Z, Jones A, Widschwendter M, Teschendorff AE. An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. *Genome Biol*. 2015;16:140.
- Sahnane N, Magnoli F, Bernasconi B, Tibiletti MG, Romualdi C, Pedroni M, et al. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. *Clin Epigenetics*. 2015;7:131.
- Lee S-T, Wiemels JL. Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. *Nucleic Acids Res*. 2016;44:1105–17.

6. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. *Nat Rev Genet.* 2012;13:679–92.
7. Schübeler D. Function and information content of DNA methylation. *Nature.* 2015;517:321–6.
8. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer.* 2011;11:426–37.
9. Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. *Ann Surg Oncol.* 2011;18:2461–8.
10. Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. *Gynecol Oncol.* 2011;120:113–20.
11. Radpour R, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. *PLoS One.* 2011;6:e16080.
12. Langevin SM, Koestler DC, Christensen BC, Butler RA, Wiencke JK, Nelson HH, et al. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. *Epigenetics.* 2012;7:291–9.
13. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, et al. Epigenetic alteration: new insights moving from tissue to plasma—the example of PCDH10 promoter methylation in colorectal cancer. *Br J Cancer.* 2013;109:807–13.
14. Klotten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. *Breast Cancer Res.* 2013;15:R4.
15. Salvianti F, Orlando C, Massi D, De Giorgi V, Grazzini M, Pazzagli M, et al. Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma. *Front Mol Biosci.* 2015;2:76.
16. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. *Int J Cancer.* 2013;133:346–56.
17. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. *Sci Transl Med.* 2012;4:162ra154.
18. Chan KCA, Jiang P, Zheng YWL, Liao GJW, Sun H, Wong J, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. *Clin Chem.* 2013;59:211–24.
19. Chan KCA, Jiang P, Chan CWM, Sun K, Wong J, Hui EP, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. *Proc Natl Acad Sci U S A.* 2013;110:18761–8.
20. Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VW-S, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. *Proc Natl Acad Sci U S A.* 2015;112:E1317–25.
21. Sun K, Jiang P, Chan KCA, Wong J, Cheng YKY, Liang RHS, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. *Proc Natl Acad Sci U S A.* 2015;112:201508736.
22. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheimer J, Vaknin-Dembinsky A, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. *Proc Natl Acad Sci U S A.* 2016;113:201519286.
23. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. *Cell.* 2016;164:57–68.
24. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics.* 2011;27:1571–2.
25. Shen-Orr SS, Tibshirani R, Khatri P, Bodian DL, Staedtler F, Perry NM, et al. Cell type-specific gene expression differences in complex tissues. *Nat Methods.* 2010;7:287–9.
26. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics.* 2012;13:86.
27. Joshi AJ, Porikli F, Papanikolopoulos NP. Scalable active learning for multiclass image classification. *IEEE Trans Pattern Anal Mach Intell.* 2012;34:2259–73.
28. Gupta MR, Bengio S, Weston J. Training highly multiclass classifiers. *J Mach Learn Res.* 2014;15:1461–92.
29. Kang S, Cho S, Kang P. Constructing a multi-class classifier using one-against-one approach with different binary classifiers. *Neurocomputing.* 2015;149:677–82.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

